38 results on '"Wijermans, P"'
Search Results
2. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON
3. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT)
4. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
5. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
6. Bortezomib before and after high-dose chemotherapy improves the survival in patients with newly diagnosed multiple myeloma and renal insufficiency - a subgroup analysis of the prospective randomised GMMG HD4/HOVON 65 study: V817
7. Bortezomib during induction and maintenance before and after autologous transplantation improves overall survival in patients with renal impairment: subgroup analysis from the HOVON-65/GMMG-HD4 randomized trial for newly diagnosed multiple myeloma: O270
8. Red Cell Exchange Transfusions Lead to Decreased Platelet Aggregation and Activation in Patients with Sickle Cell Disease: S76-030J
9. First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) vs. VAD as Induction Treatment Prior to High-dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM): B152
10. The Dutch Lenalidomide Named Patient Program: Results and Feasibility in Heavily Pretreated Patients: A285
11. MP versus MPT in Elderly Myeloma Patients: The Final Outcome of the HOVON-49 Study: A116
12. HOVON-50 Final Analysis of Thalidomide Combined with Adriamycin, Dexamethasone, and HDM: A046
13. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine
14. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients
15. Epigenetic therapy in MDS and acute AML: focus on decitabine
16. Splenectomy for the treatment of thrombotic thrombocytopenic purpura
17. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
18. Interferon-α as maintenance therapy in patients with multiple myeloma
19. Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas
20. Low-Dose Decitabine in Older MDS Patients: Results of Re-Treatment in Decitabine-Responsive Patients: O351
21. Early response to therapy and survival in multiple myeloma
22. The impact of post-remission therapy on outcome of patients with poor risk MDS and secondary AML (sAML) treated with intensive chemotherapy with or without stem cell transplantation in a joint study
23. A matched pair analysis of hospitalization and survival in high-risk MDS patients with low-dose decitabine: P669
24. Acute myeloid leukemia of the elderly and frail: Treatment with low-dose 5-aza-2ʼdeoxycytidine (Decitabine): P584
25. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921)
26. Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry
27. Disappearance of a mucosa-associated lymphoid tissue (MALT) lymphoma of the urinary bladder after treatment for Helicobacter pylori
28. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study
29. Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
30. Comparison of single and dual-platform assay formats for CD34+ haematopoietic progenitor cell enumeration
31. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma
32. AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR PATIENTS WITH POOR RISK MDS AND SECONDARY AML (sAML)
33. EFFICACY OF STANDARD CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH POOR RISK NON-HODGKIN'S LYMPHOMA (NHL)
34. VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) FOLLOWED BY STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: RESULTS OF A PHASE II AND PRELIMINARY RESULTS OF A RANDOMISED PHASE III STUDY
35. A population-based registry on paraproteinaemia in the Netherlands
36. An IVS1-116 (A->G) acceptor splice site mutation in the alpha2 globin gene causing alpha+ thalassaemia in two Dutch families
37. Systemic Fusarium nygamai infection in a patient with lymphoblastic non-Hodgkin's lymphoma
38. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.